Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

CRL | Charles River Laboratories International Inc.

IndexS&P 500 P/E20.35 EPS (ttm)9.42 Insider Own1.90% Shs Outstand50.94M Perf Week-1.42%
Market Cap9.83B Forward P/E16.82 EPS next Y11.40 Insider Trans-0.87% Shs Float50.30M Perf Month-8.56%
Income484.03M PEG4.20 EPS next Q2.36 Inst Own99.94% Short Float / Ratio3.38% / 3.66 Perf Quarter-7.37%
Sales4.18B P/S2.35 EPS this Y-5.14% Inst Trans3.28% Short Interest1.70M Perf Half Y-4.28%
Book/sh63.43 P/B3.02 EPS next Y8.04% ROA6.33% Target Price244.31 Perf Year-2.60%
Cash/sh4.05 P/C47.34 EPS next 5Y4.84% ROE16.41% 52W Range181.22 - 262.00 Perf YTD-12.03%
Dividend- P/FCF33.96 EPS past 5Y30.13% ROI7.64% 52W High-26.84% Beta1.33
Dividend %- Quick Ratio1.21 Sales past 5Y16.52% Gross Margin33.63% 52W Low5.77% ATR5.25
Employees21400 Current Ratio1.49 Sales Q/Q8.92% Oper. Margin15.53% RSI (14)36.11 Volatility1.92% 2.63%
OptionableYes Debt/Eq0.95 EPS Q/Q-11.57% Profit Margin11.58% Rel Volume0.68 Prev Close193.39
ShortableYes LT Debt/Eq0.95 EarningsAug 09 BMO Payout0.00% Avg Volume464.28K Price191.68
Recom1.69 SMA20-4.78% SMA50-6.29% SMA200-8.99% Volume317,735 Change-0.88%
Date Action Analyst Rating Change Price Target Change
Sep-13-23Initiated TD Cowen Market Perform $212
Jul-10-23Downgrade Citigroup Buy → Neutral $260 → $225
Feb-23-23Upgrade Guggenheim Neutral → Buy $255
Jan-12-23Downgrade Jefferies Buy → Hold
Sep-30-22Upgrade Jefferies Hold → Buy $240
Aug-25-22Initiated Credit Suisse Outperform $285
Aug-04-22Downgrade Morgan Stanley Overweight → Equal-Weight $350 → $250
May-24-22Initiated Guggenheim Neutral
Apr-25-22Downgrade Jefferies Buy → Hold $370 → $280
Apr-07-22Initiated Stephens Overweight $377
Oct-02-23 11:35AM
Sep-27-23 12:04PM
Sep-26-23 08:02AM
08:00AM
Sep-25-23 11:40AM
08:00AM Loading…
08:00AM
Sep-21-23 11:36AM
Sep-20-23 08:30AM
Sep-18-23 12:03PM
Sep-15-23 08:36AM
Sep-14-23 08:00AM
Sep-12-23 11:33AM
Sep-11-23 08:00AM
Sep-08-23 11:30AM
Sep-06-23 03:02PM
10:35AM Loading…
10:35AM
08:00AM
Aug-30-23 07:32PM
05:40PM
Aug-24-23 06:24PM
08:00AM
Aug-10-23 01:42PM
Aug-09-23 02:50PM
12:33PM
12:13PM
11:12AM
09:30AM
08:29AM
08:15AM
07:10AM
07:00AM Loading…
07:00AM
Aug-04-23 04:04PM
03:32PM
Aug-03-23 06:05PM
Aug-02-23 11:31AM
Aug-01-23 08:00AM
Jul-31-23 11:30AM
Jul-21-23 01:40PM
01:25PM
Jul-20-23 12:54PM
Jul-19-23 08:00AM
Jul-17-23 10:27AM
Jul-04-23 07:32AM
Jun-14-23 11:21AM
08:50AM
07:24AM
Jun-13-23 09:45AM
04:30AM
Jun-12-23 08:00AM
Jun-09-23 08:53AM
Jun-08-23 04:30PM
Jun-05-23 08:00AM
Jun-01-23 11:17AM
May-31-23 11:35AM
08:00AM
May-17-23 10:35AM
May-14-23 04:05PM
10:28AM
May-12-23 01:31AM
May-11-23 08:04PM
12:25PM
11:42AM
09:39AM
09:30AM
08:15AM
07:00AM
May-01-23 11:14AM
08:00AM
Apr-24-23 06:21PM
Apr-12-23 12:33PM
12:33PM
Apr-11-23 08:30AM
Apr-10-23 08:00AM
Apr-09-23 08:59AM
Mar-31-23 08:02AM
Mar-24-23 11:30AM
Mar-16-23 07:30AM
Mar-15-23 03:14PM
Mar-14-23 08:28AM
Mar-13-23 08:00AM
08:00AM
Mar-09-23 08:00AM
Mar-03-23 04:59PM
Mar-02-23 05:18AM
Feb-27-23 07:56AM
06:50AM
Feb-23-23 07:25PM
04:33PM
05:17AM
Feb-22-23 07:22PM
04:18PM
04:03PM
02:47PM
02:34PM
01:57PM
01:19PM
11:55AM
09:38AM
08:40AM
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment consists of the commercial production and sale of research models, research products, and the provision of services related to the maintenance and monitoring of research models and the management of the clients? research operations. The Discovery and Safety Assessment segment offers integrated drug discovery services directed at the identification, screening, and selection of a lead compound for drug development and offers safety assessment services, including bioanalysis, drug metabolism, pharmacokinetics, toxicology, and pathology. The Manufacturing Support segment consists of Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services, Biologics Solutions, which performs specialized testing of biologics as well as contract development and manufacturing, and Avian Vaccine Services, which supplies specific-pathogen-free chicken eggs and chickens. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WALLMAN RICHARD FDirectorAug 24Buy198.791,000198,7861,000Aug 29 04:23 PM
Barbo William DCorporate Executive VP & CCOAug 10Option Exercise144.675,511797,2769,103Aug 14 04:17 PM
Knell Michael GunnarCSVP&Chief Accounting OfficerAug 10Option Exercise144.671,471212,81011,411Aug 14 04:15 PM
Barbo William DCorporate Executive VP & CCOAug 10Sale217.245,7631,251,9543,592Aug 14 04:17 PM
Knell Michael GunnarCSVP&Chief Accounting OfficerAug 10Sale216.541,471318,5309,940Aug 14 04:15 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopAug 10Sale216.52700151,56424,983Aug 14 04:11 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopMay 15Sale190.3934565,68524,026May 16 02:18 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopMay 12Sale193.03959185,11624,371May 15 02:49 PM
MASSARO GEORGEDirectorMay 11Sale193.4328855,7084,964May 15 02:42 PM
WALLMAN RICHARD FDirectorFeb 23Buy220.731,750386,27821,864Feb 24 04:20 PM
Parisotto Shannon MCEVP, Disc & Safety AssessmentFeb 16Option Exercise109.344,558498,37210,568Feb 21 05:39 PM
Girshick BirgitCorporate Executive VP & COOFeb 16Option Exercise109.343,205350,43544,243Feb 17 05:29 PM
Parisotto Shannon MCEVP, Disc & Safety AssessmentFeb 16Sale254.414,5581,159,6196,010Feb 21 05:39 PM
Girshick BirgitCorporate Executive VP & COOFeb 16Sale254.393,205815,31041,038Feb 17 05:29 PM
FOSTER JAMES CChairman, President and CEOFeb 15Sale250.0020,0005,000,017216,594Feb 17 04:02 PM
Barbo William DCorporate Executive VP & CCODec 02Option Exercise109.343,205350,4357,008Dec 06 04:40 PM
WALLMAN RICHARD FDirectorDec 02Buy218.901,500328,35020,114Dec 06 04:12 PM
Barbo William DCorporate Executive VP & CCODec 02Sale219.913,205704,8143,803Dec 06 04:40 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopDec 01Option Exercise109.346,409700,76026,641Dec 05 04:55 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopDec 01Sale224.256,4091,437,20520,232Dec 05 04:55 PM
Knell Michael GunnarCSVP&Chief Accounting OfficerNov 16Option Exercise109.3485593,4867,293Nov 17 05:27 PM
Knell Michael GunnarCSVP&Chief Accounting OfficerNov 16Sale248.59855212,5446,438Nov 17 05:27 PM
Parisotto Shannon MCEVP, Disc & Safety AssessmentNov 15Option Exercise109.342,279249,1864,778Nov 17 05:22 PM
Parisotto Shannon MCEVP, Disc & Safety AssessmentNov 15Sale249.902,279569,5222,499Nov 17 05:22 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopNov 04Sale216.36534115,53620,232Nov 07 06:54 PM